- About ACRO
- ACRO Updates
- Policy Views
- Meetings + Events
- Media Center
- Contact Us
Contact: Leslie Irvine
ACRO Takes To Video To Advise FDA on Innovation
May 16, 2012 - WASHINGTON, DC – Building on its recent testimony to the FDA on modernizing clinical trials, the Association of Clinical Research Organizations (ACRO) has released a new video exhorting the FDA to demonstrate “bold leadership” to help make the drug development process less expensive, faster and more productive.
Noting that eight years have passed since the issuance of the agency’s “Critical Path” whitepaper, ACRO Executive Director Doug Peddicord, Ph.D. calls for an audit of the FDA’s actions to date to advance innovation in the conduct and oversight of clinical trials.
Peddicord also recommends the FDA appoint a chief innovation officer with “…broad authority to approve innovative approaches to drug development so that industry can be comfortable experimenting within an appropriate, agreed-upon regulatory framework.”
The Association of Clinical Research Organizations (ACRO) represents companies that provide a variety of specialized services that support the development of new pharmaceuticals, biologics and medical devices. The association provides an active voice for the CRO industry globally. Through its member companies, ACRO helps improve the quality, efficiency and safety of biomedical research. ACRO member companies employ approximately 75,000 professionals worldwide and annually conduct more than 11,000 clinical trials involving nearly two million participants in 115 countries. For more information, please visit www.acrohealth.org. Twitter @acrohealth. YouTube @ACROHealthChannel.
###Download as PDF